Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma

PURPOSE: A randomized, phase III, placebo-controlled, partially blinded clinical trial (REGAL [Recentin in Glioblastoma Alone and With Lomustine]) was conducted to determine the efficacy of cediranib, an oral pan–vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, either as...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Batchelor, Tracy T., Mulholland, Paul, Neyns, Bart, Nabors, L. Burt, Campone, Mario, Wick, Antje, Mason, Warren, Mikkelsen, Tom, Phuphanich, Surasak, Ashby, Lynn S., DeGroot, John, Gattamaneni, Rao, Cher, Lawrence, Rosenthal, Mark, Payer, Franz, Jürgensmeier, Juliane M., Jain, Rakesh K., Sorensen, A. Gregory, Xu, John, Liu, Qi, van den Bent, Martin
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2013
Témata:
Original Reports
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4021043/
https://ncbi.nlm.nih.gov/pubmed/23940216
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.47.2464
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky